Simulations Plus, Inc. (SLP)
NASDAQ: SLP · Real-Time Price · USD
15.88
+0.17 (1.08%)
At close: May 6, 2026, 4:00 PM EDT
15.74
-0.14 (-0.88%)
After-hours: May 6, 2026, 7:57 PM EDT
Simulations Plus Revenue
Simulations Plus had revenue of $24.29M in the quarter ending February 28, 2026, with 19.29% growth. This brings the company's revenue in the last twelve months to $80.54M, up 0.19% year-over-year. In the fiscal year ending August 31, 2025, Simulations Plus had annual revenue of $79.18M with 13.09% growth.
Revenue (ttm)
$80.54M
Revenue Growth
+0.19%
P/S Ratio
3.98
Revenue / Employee
$378,099
Employees
213
Market Cap
320.86M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Aug 31, 2025 | 79.18M | 9.17M | 13.09% |
| Aug 31, 2024 | 70.01M | 10.44M | 17.52% |
| Aug 31, 2023 | 59.58M | 5.67M | 10.52% |
| Aug 31, 2022 | 53.91M | 7.44M | 16.01% |
| Aug 31, 2021 | 46.47M | 4.88M | 11.73% |
| Aug 31, 2020 | 41.59M | 7.62M | 22.43% |
| Aug 31, 2019 | 33.97M | 4.30M | 14.51% |
| Aug 31, 2018 | 29.67M | 5.53M | 22.90% |
| Aug 31, 2017 | 24.14M | 4.17M | 20.86% |
| Aug 31, 2016 | 19.97M | 1.66M | 9.05% |
| Aug 31, 2015 | 18.31M | 6.85M | 59.80% |
| Aug 31, 2014 | 11.46M | 1.39M | 13.80% |
| Aug 31, 2013 | 10.07M | 622.19K | 6.58% |
| Aug 31, 2012 | 9.45M | 709.87K | 8.12% |
| Aug 31, 2011 | 8.74M | -1.97M | -18.42% |
| Aug 31, 2010 | 10.71M | 1.57M | 17.16% |
| Aug 31, 2009 | 9.14M | 175.30K | 1.95% |
| Aug 31, 2008 | 8.97M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Evolent Health | 1.88B |
| Claritev | 965.41M |
| Phreesia | 480.59M |
| TruBridge | 346.84M |
| Weave Communications | 248.72M |
| So-Young International | 217.80M |
| LifeMD | 194.06M |
| NRC Health | 138.64M |
SLP News
- 12 hours ago - Simulations Plus Collaborates With Nvidia During AI Drug Modeling Push - Benzinga
- 16 hours ago - Simulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling Workflows - Business Wire
- 15 days ago - Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products - Business Wire
- 16 days ago - Simulations Plus Expands Global Access to Model-Informed Drug Development Training Through Its 2026 Spring School - Business Wire
- 27 days ago - Simulations Plus Earnings Call Transcript: Q2 2026 - Transcripts
- 27 days ago - Simulations Plus Reports Second Quarter Fiscal 2026 Financial Results - Business Wire
- 5 weeks ago - Simulations Plus Announces Second Quarter Fiscal Year 2026 Earnings and Conference Call Date - Business Wire
- 5 weeks ago - Simulations Plus Announces Strategic Collaboration Programs for AI-Enabled Modeling - Business Wire